Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. The prevalence of PD increases dramatically with age, affecting 1–2% of the population above 65 years (1,2). PD is characterized by a progressive loss of dopaminergic neurons in the substantia nigra, pars compacta in the brain stem. The classical symptoms are tremor, rigidity, and slowness of movements. The symptoms appear when about 70% of the dopaminergic neurons are lost, demonstrating that the degenerative process is active long before the patients become aware of the disease. In the degenerating neurons, proteinaceous inclusions named Lewy bodies are found in the cell body and Lewy neurites in the neuronal processes (3). The inclusions exhibit filamentous protein aggregates with α-synuclein being a prominent component (4–7). The definitive diagnosis of PD requires both the clinical symptoms and post mortem examination. No preventive or neuroprotective therapies exist for PD, of which treatment primarily relies on substitution therapy with dopamine precursors or agonists. Genetic predispositions as well as environmental factors increase the risk of PD, but the etiology of PD is largely unknown. In rare familial cases, PD is linked to mutations in single genes encoding α-synuclein and parkin proteins. These cases have shed light on mechanisms leading to the selective dopaminergic cell loss.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., et al. (1997) Prevalence of Parkinsonism and Parkinson’s Disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. J. Neurol. Neurosurg. Psychiatry 62, 10–15.
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M., Dartigues, J. F., Baldereschi, M., et al. (2000) Prevalence of Parkinson’s Disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S21–S23.
Lang, A. E. and Lozano, A. M. (1998) Parkinson’s disease. first of two parts. N. Engl. J. Med. 339, 1044–1053.
Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884.
Irizarry, M. C., Growdon, W., Gomez-Isla, T., Newell, K., George, J. M., Clayton, D. F., and Hyman, B. T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334–337.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469–6473.
Jenner, P. and Olanow, C. W. (1998) Understanding cell death in Parkinson’s disease. Ann. Neurol. 44, S72–S84.
Tatton, N. A. (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp. Neurol. 166, 29–43.
Schlossmacher, M. G., Frosch, M. P., Gai, W. P., Medina, M., Sharma, N., Forno, L., et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655–1667.
Jensen, P. H., Islam, K.; Kenney, J., Nielsen, M. S., Power, J., and Gai, W. P. (2000) Microtubule-associated protein 1B is a component of cortical lewy bodies and binds alpha-synuclein filaments. J. Biol. Chem. 275, 21,500–21,507.
Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., et al. (1999) Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843–9846.
Galvin, J. E., Lee, V. M., Schmidt, M. L., Tu, P. H., Iwatsubo, T., and Trojanowski, J. Q. (1999) Pathobiology of the Lewy body. Adv. Neurol. 80, 313–324.
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. (1998) Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608.
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., et al. (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395, 451–452.
Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev. Biochem. 67, 425–479.
Mori, K. (2000) Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 101, 451–454.
Imai, Y., Soda, M., and Takahashi, R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35,661–35,664.
Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., and Takahashi, R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891–902.
Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Nakayama, K. I., and Takahashi, R. (2002) CHIP is associated with Parkin, a gene responsible for familial Parkinson’s disease, and enhances its ubiquitin ligase activity. Mol. Cell 10, 55–67.
Ledesma, M. D., Galvan C., Hellias B., Dotti C., and Jensen, P. H. (2002) Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J. Neurochem. 83, 1431–1440.
Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318–1320.
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M.; et al. (1993) Molecular cloning of CDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11,282–11,286.
Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., and Goedert, M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J. Biol. Chem. 273, 26,292–26,294.
Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252.
Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., and Lee, V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214–3220.
Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27–32.
Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., and Mouradian, M. M. (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274, 33,855–33,858.
Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., et al. (2000) Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J. Biol. Chem. 275, 390–397.
Tofaris, G. K., Layfield, R., and Spillantini, M. G. (2001) Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22–26.
Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., et al. (2001) Ubiquitination of a new form of alpha-synuclein by Parkin from human brain: implications for Parkinson’s disease. Science 293, 263–269.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047.
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108.
Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Odoy, S., Okamoto, N., et al. (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215–2225.
Feany, M. B. and Bender, W. W. (2000) A Drosophila model of Parkinson’s disease. Nature 404, 394–398.
Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11,604–11,613.
Lashuel, H., Petre, B., Wall, J., Simon, M., Nowak, R., Walz, T., and Lansbury, P. (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102.
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164.
Giasson, B. I., Duda, J. E., Murray, I. V., Chen, Q., Souza, J. M., Hurtig, H. I., et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985–989.
Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865–868.
Zhang, Y., Gao, J., Chung, K. K., Huang, H., Dawson, V. L., and Dawson, T. M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the syaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97, 13,354–13,359.
Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., et al. (2000) Familial Parkinson disease gene product, Parkin, Is a ubiquitin-protein ligase. Nat. Genet. 25, 302–305.
Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., et al. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144–1150.
Lücking C., Düur A., Bonifati V., Vaughan J., de Michele G., Gasser T., et al. (2000) Association between early-onset Parkinson’s disease and mutations in the Parkin gene. N. Engl. J. Med. 342, 1560–1567.
Zarate-Lagunes, M., Gu, W. J., Blanchard, V., Francois, C., Muriel, M. P., Mouatt-Prigent, A., et al. (2001) Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes. J. Comp. Neurol. 432, 184–196.
Shimura, H., Hattori, N., Kubo, S., Yoshikawa, M., Kitada, T., Matsumine, H., et al. (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668–672.
Kahns, S., Lykkebo, S., Jakobsen, L. D., Nielsen, M. S., and Jensen, P. H. (2002) Caspase-mediated Parkin cleavage in apoptotic cell death. J. Biol. Chem. 277, 15,303–15,308.
Wakabayashi, K., Engelender, S., Yoshimoto, M., Tsuji, S., Ross, C. A., and Takahashi, H. (2000) Synphilin-1 is present in Lewy bodies in Parkinson’s disease. Ann. Neurol. 47, 521–523.
Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., et al. (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51, 890–892.
Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., et al. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord. 15, 884–888.
Takahashi, H., Ohama, E., Suzuki, S., Horikawa, Y., Ishikawa, A., Morita, T., et al. (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44, 437–441.
van de Warrenburg, B. P., Lammens, M., Lucking, C. B., Denefle, P., Wesseling, P., Booij, J., et al. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555–557.
Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293–300.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Jakobsen, L.D., Jensen, P.H. (2003). Parkinson’s Disease. In: Bross, P., Gregersen, N. (eds) Protein Misfolding and Disease. Methods in Molecular Biology™, vol 232. Humana Press. https://doi.org/10.1385/1-59259-394-1:57
Download citation
DOI: https://doi.org/10.1385/1-59259-394-1:57
Publisher Name: Humana Press
Print ISBN: 978-1-58829-065-6
Online ISBN: 978-1-59259-394-1
eBook Packages: Springer Protocols